Oger J J, Antel J P, Kuo H H, Arnason B G
Ann Neurol. 1982 Feb;11(2):177-81. doi: 10.1002/ana.410110211.
In vitro immune function was assessed in patients with multiple sclerosis (MS) who were receiving Imuran therapy, in untreated MS patients, and in controls. In untreated stable MS patients, concanavalin A (Con A)-driven mitogenic reactivity (T effector function) and Con A-induced suppressor activity were modestly reduced compared to controls; pokeweed mitogen-induced immunoglobulin G (IgG) secretion was increased. Untreated patients with active MS demonstrated high levels of IgG secretion and marked decreases in suppressor activity. In Imuran-treated patients, Con A mitogenic responses and suppressor activity were comparable to those observed in untreated stable patients, and IgG secretion was reduced. The results in the treated patients likely reflect a direct effect of Imuran on B cell function rather than an indirect effect mediated via suppressor cells.
对正在接受硫唑嘌呤治疗的多发性硬化症（MS）患者、未经治疗的MS患者及对照组进行了体外免疫功能评估。在未经治疗的稳定MS患者中，与对照组相比，伴刀豆球蛋白A（Con A）驱动的促有丝分裂反应性（T效应功能）和Con A诱导的抑制活性略有降低；商陆有丝分裂原诱导的免疫球蛋白G（IgG）分泌增加。未经治疗的活动性MS患者表现出高水平的IgG分泌且抑制活性显著降低。在接受硫唑嘌呤治疗的患者中，Con A促有丝分裂反应和抑制活性与未经治疗的稳定患者中观察到的相当，且IgG分泌减少。治疗患者的结果可能反映了硫唑嘌呤对B细胞功能的直接作用，而非通过抑制细胞介导的间接作用。
